Sygnature Discovery is a leading centre of excellence for integrated drug discovery offering significant expertise across a wide range of therapeutic areas and biological targets. More than 80% of our scientists have PhDs and have been recruited internationally, many having undertaken post-doctoral research at world renowned universities. Sygnature’s research scientists also bring considerable pharmaceutical industry experience which is applied to every research project we undertake.
Sygnature’s dynamic blend of industry-experienced and recently qualified research scientists is further enhanced through our unique approach of having medicinal chemists, in vitro biologists and DMPK scientists are co-located in the same laboratories to efficiently advance our clients’ drug discovery projects into pre-clinical development, resulting in 5 clinical candidates for our clients in 2015.
Key areas of expertise include oncology, respiratory diseases, metabolic disease, orphan indications and CNS disorders. Sygnature brings such expertise to fully integrated programmes as well as medicinal chemistry, bioscience, computational chemistry or DMPK only projects. This flexible approach is tailored to your specific requirements and fully project managed.
- Anti-infectives (anti-virals and anti-microbials)
- CNS (neurodegeneration, psychiatry and pain)
- Metabolic diseases
- Orphan indications
- Respiratory disorders (asthma, COPD and cystic fibrosis)
- Epigenetic targets
- Ion channels
- Nuclear receptors
- Protein-protein interactions